Medical Oncology

Gastroesophageal Cancer

Questions discussed in this category

How do you treat locally advanced, operable, Siewert 3 GE junction adenocarcinomas?

Would you consider adjuvant nivolumab to be the standard of care in stage II/III esophageal/GE junction cancer after completion of neoadjuvant chemoradiotherapy and surgery?

Based on CheckMate 577?Is DFS endpoint sufficient to establish SOC or is OS benefit needed?

4 Answers available

Would you offer local therapy to a patient with GEJ adenocarcinoma with FDG-avid para-aortic node oligometastasis?

For nodes just inferior to the celiac/SMA axis and no other distant metastatic disease? Stage is formally M1, but just barely. The patient is otherwis...

2 Answers available

What maintenance therapy, if any, do you offer patients with metastatic HER2+ esophageal or gastric cancer?

What combination of fluoropyrimidine, PD-1 inhibitor, or trastuzumab do you use?

0 Answers available

Would you offer immunotherapy in addition to chemotherapy and trastuzumab for patients with metastatic HER2 positive gastroesophageal cancer with low PDL1?

KEYNOTE 811 showed improved response rate with the addition of pembrolizumab, but very few patients in this study had low PDL1.

1 Answer available

For a patient with distal esophageal adenocarcinoma with residual disease after FOLFOX x3 cycles + RT followed by surgery, would you recommend adjuvant chemotherapy or adjuvant nivolumab?

Would you ever consider adjuvant chemotherapy rather than adjuvant immunotherapy after the publication of the CM-577 results? If so, in which pop...

3 Answers available

Can the results of Checkmate 577 be applied to patients who do not undergo surgery following chemoradiation because of a clinical complete response?

What about for a patient with complete radiographic response who declines surgical management?

3 Answers available

How does use of adjuvant nivolumab impact your subsequent use of immunotherapy + chemo in a PDL1+ GEJ cancer with metastatic relapse?

What factors would influence your approach?

3 Answers available

Should we be giving adjuvant nivolumab to all eligible esophageal/GEJ cancer, irrespective of the PD-L1 status of the tumor?

Are there other treatment variations by clinical subsets (eg tumor location, histology, stage II vs III, other biomarkers) seen in CM577 or other data...

3 Answers available

What would your initial treatment be for an elderly patient with metastatic HER2+ GEJ cancer with PD-L1 <5 who cannot tolerate any platinum agents?

2 Answers available

What first line treatment would you consider for a patient with stage IV gastric cancer that is HER2 negative and MSI-high?

1 Answer available

Would you consider offering neoadjuvant concurrent chemoradiation to a young (<50) patient with adenocarcinoma of the GE junction with a site of solitary metastasis (bone)?

Provided the patient can have the solitary met treated definitively with SBRT and is otherwise a good surgical candidate

1 Answer available

Would you consider perioperative immunotherapy for a patient with locally advanced, resectable gastric cancer but not a candidate for chemotherapy?

On occasion, patients with locally advanced gastric cancer are poor candidates for FLOT-like chemotherapy. Should such patients be taken to surgery up...

1 Answer available

Is there a role for a PDL-1 inhibitor in patients with chemo-refractory metastatic esophageal adenocarcinoma with PDL negative, MSI stable disease?

In a patient with a good performance status, would you consider this?

0 Answers available

How do you manage postoperative residual disease after neoadjuvant chemoradiotherapy and surgery for a patient with locally advanced esophageal or GE junction adenocarcinoma?

0 Answers available

Do you recommend adjuvant chemoradiation for T2N0 gastric adenocarcinoma?

In a patient with an R0 resection, would you routinely recommend postop chemoradiation, since these patients were included in the MacDo...

1 Answer available